The MFDS (Director Oh Yoo-kyung) announced on the 15th that it will change the efficacy, and indication precautions of "JAK Inhibitor", which is used as a treatment for inflammatory diseases.

Patients can be used the same as before, but high-risk patients such as those aged 65 or older, high-risk cardiovascular groups, and risk of malignancy will be available only if the effect is insufficient with the existing treatment. JAK Inhibitor is used to treat various inflammatory diseases such as rheumatoid arthritis by blocking the action of JAK, an enzyme that controls immunity and inflammation, and 65 items of Tofacitinib, Baricitinib, Upacitinib, Abrocitinib, and Filgotinib are licensed in Korea.